United States securities and exchange commission logo





                           June 10, 2020

       Eric A. Adams
       President and Chief Executive Officer
       InMed Pharmaceuticals Inc.
       Suite 310-815 W. Hastings Street
       Vancouver, B.C. V6C 1B4
       Canada

                                                        Re: InMed
Pharmaceuticals Inc.
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted May 27,
2020
                                                            CIK No. 0001728328

       Dear Mr. Adams:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 1 to Draft Registration Statement on Form S-1 submitted
May 27, 2020

       Prospectus Summary
       Overview, page 2

   1.                                                   We note your response
to comment 2. The prospectus summary should provide a brief,
                                                        but balanced,
description of the key aspects of your business. Please balance your
                                                        statement that your
approach leverages the history of health benefits attributed to the
                                                        cannabis plant with
disclosure in this "Overview" section that the U.S. Food and Drug
                                                        Administration (FDA)
has, to date, not approved any marketing application for cannabis
                                                        for the treatment of
any disease or condition and has approved only one cannabis-derived
                                                        and three
cannabis-related drug products. Additionally, we note your response to comment
 Eric A. Adams
FirstName LastNameEric A. Adams
InMed Pharmaceuticals Inc.
Comapany NameInMed Pharmaceuticals Inc.
June 10, 2020
June 10, 2020 Page 2
Page 2
FirstName LastName
         3, which we reissue. Please provide a discussion of the risks and
challenges you face in
         implementing your business plan that is dependent on your
biosynthesis-based
         manufacturing system, e.g. the need to scale up manufacturing capacity
from current
         limited levels, as discussed on page 42.
INM-755 in Dermatology, page 4

2.       We note your response to comment 8 and your revised disclosure stating
that "[a]s
         assessed by the Netherlands National Competent Authority and Ethics
Committee, the
         findings from our toxicology studies supported the safety of CBN for
Phase I clinical
         development studies in healthy volunteers." Safety is assessed
throughout all phases of
         clinical trials. As your product candidates have not completed
clinical trials, your product
         candidates have not been determined to be safe. Therefore, it is
inappropriate to state or
         imply that your product candidates will be determined to be safe.
Please revise your
         disclosure to remove such implication here and throughout your
registration
         statement. We will not object to statements that your product
candidate was well-
         tolerated. Additionally, please revise your disclosure to clarify, if
true, that the disclosure
         in the third paragraph of this section relates to your Phase 1 study
(755-101-HV)
         discussed in the paragraph above.
Business
Our Product Candidates and Technologies
Key Milestones, page 78

3.       We note your response to comment 12. Please further revise your
description of the
         Collaborative Research Agreements and Technology Assignment Agreements
with
         the University of British Columbia to disclose the termination
provisions and the term of
         your royalty obligations, respectively.
INM-088 for the Treatment of Glaucoma, page 100

4.       We note your response to comment 16. Please revise your
characterization of the INM-
         088 preclinical trials to discuss the actual data from the preclinical
trials, rather than
         drawing conclusions from the results. As illustrative examples only,
we note the following
         disclosures:

              CBN has a significant anti-apoptotic effect on differentiated
RGCs when subjected to
              elevated hydrostatic pressure.....Exposure of these cells under
the same conditions
              concurrently with CBN prevented apoptosis and resulted in a
significantly higher
              level of cell survival.
              reduction in IOP and improvement of pERG amplitudes were used to
demonstrate
              effectiveness of CBN as a potential glaucoma treatment.
 Eric A. Adams
InMed Pharmaceuticals Inc.
June 10, 2020
Page 3


Intellectual Property , page 110

5.     We note your response to comment 17. Please revise to identify the
material jurisdictions
       where patent applications are pending. Please also provide estimated
expiry dates if the
       applications are approved.
       You may contact Ibolya Ignat at 202-551-3636 or Terence O'Brien at
202-551-3355 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jeffrey Gabor at 202-551-2544 or Christine Westbrook at 202-551-5019
with any other
questions.



                                                           Sincerely,
FirstName LastNameEric A. Adams
                                                           Division of
Corporation Finance
Comapany NameInMed Pharmaceuticals Inc.
                                                           Office of Life
Sciences
June 10, 2020 Page 3
cc:       Daniel M. Miller, Esq.
FirstName LastName